Abstract 1563
Background
FOLFIRINOX (5FU, folinic acid [FA], irinotecan [Iri], oxaliplatin [Ox]) is a 1st-line standard in fit Pts with aPDAC. Anti-PD-(L)1 as single agents have failed in aPDAC and new combination immunotherapies are needed. Tedopi (OSE2101) is a multiple neoepitope vaccine restricted to HLA-A2 positive Pts targeting 5 tumor-associated antigens (ACE, HER2, MAGE2, MAGE3, TP53) frequently expressed in PDAC. This study aims to assess the efficacy and safety of Tedopi alone and in combination with anti-PD-1 nivolumab or FOLFIRI as maintenance therapy in aPDAC Pts after FOLFIRINOX induction CT.
Trial design
TEDOPaM is a 3-arm, Fleming 2-stage, open-label, randomized, non-comparative phase II study. 156 Pts with recurrent or advanced, pathologically proven PDAC; ECOG PS 0-1; HLA-A2 genotype; controlled disease (PR or SD) after 8 cycles of FOLFIRINOX; adequate organ functions, are randomized (1:1:1, stratified on center, tumor stage, best response to FOLFIRINOX) into 3 arms:Table:
830TiP
Arm A (reference): FOLFIRI (n = 52) | IV; FA 400 mg/m2, Iri 180 mg/m2, 5FU bolus 400 mg/m2 + continuous 2400 mg/m2/46h |
Arm B: Tedopi (n = 52) | Subcutaneous injection on D1 Q3W/6 doses then Q8W until month 12 [M12] then Q12W up to M24 |
Arm C: Tedopi + nivolumab (n = 52) | Tedopi + nivolumab 360 mg IV on D1 Q3W/6 doses then 480 mg Q4W up to M24 |
In Arms B and C, reintroduction of FOLFIRI at disease progression or unacceptable toxicity. Primary endpoint: overall survival rate at M12. Secondary: progression-free survival (CT-scan Q8W), duration of disease control, safety, response rate, RECIST v1.1/iRECIST comparison, HRQoL, Q-TWiST. Interim analysis after inclusion of 20 Pts in each arm. Translational research on tumor tissue (initial FFPE biopsy and optional re-biopsy at inclusion): RNAseq (cancer and stroma), mutation burden, MMR status, immune infiltrates; and in blood (before and on-treatment): cytokine panel, PBMC phenotyping, vaccine-antigen specific T-cells, TCR repertoire, extracellular vesicles to explore biomarkers and pharmacodynamics effects of Tedopi ± nivolumab.
Clinical trial identification
NCT03806309.
Editorial acknowledgement
Legal entity responsible for the study
GERCOR.
Funding
OSE Immunotherapeutics.
Disclosure
C. Neuzillet: Honoraria (self), Not related to the abstract: Amgen; Honoraria (self), Not related to the abstract: AstraZeneca; Research grant / Funding (institution), Not related to the abstract: Celgene; Honoraria (self), Travel / Accommodation / Expenses, Not related to the abstract: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses, PI of the TEDOPaM Clinical Trial: OSE Immunotherapeutics; Honoraria (self), Not related to the abstract: Roche; Honoraria (self), Not related to the abstract: Servier. V. Hautefeuille: Honoraria (self), Not related to the abstract: Amgen; Honoraria (self), Not related to the abstract: Novartis; Honoraria (self), Not related to the abstract: Ipsen; Honoraria (self), Not related to the abstract: Pfizer; Honoraria (self), Not related to the abstract: AAA; Honoraria (self), Not related to the abstract: Sanofi; Honoraria (self), Not related to the abstract: Merck; Honoraria (self), Not related to the abstract: Servier; Honoraria (self), Not related to the abstract: Lilly. A. Lambert: Advisory / Consultancy: Janssen; Advisory / Consultancy: Merck KGaA; Advisory / Consultancy: Bayer; Honoraria (self): Servier/Pfizer. D. Vernerey: Advisory / Consultancy: OSE Immunotherapeutics; Advisory / Consultancy: HalioDX; Advisory / Consultancy: Pfizer; Advisory / Consultancy: CellProthera. All other authors have declared no conflicts of interest.
Resources from the same session
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract